LUNG ADENOCARCINOMA
Clinical trials for LUNG ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LUNG ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for LUNG ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a new drug boost lung cancer treatment?
Disease control OngoingThis study tests whether adding the drug veliparib to standard chemoradiation helps people with stage III non-small cell lung cancer that can't be surgically removed. It first finds the best dose, then compares the combination to standard treatment alone. About 53 adults particip…
Matched conditions: LUNG ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:22 UTC
-
Radiation boost may extend life for hard-to-treat lung cancer patients
Disease control TerminatedThis study looks at whether adding radiation therapy to standard immunotherapy (with or without chemotherapy) can help people with advanced non-small cell lung cancer that lacks the PD-L1 marker. About 427 adults with stage IIIB, IIIC, or IV disease will be randomly assigned to r…
Matched conditions: LUNG ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:12 UTC
-
New targeted pill shows promise for Hard-to-Treat lung cancer
Disease control OngoingThis study tests a drug called AMG 510 in people with advanced lung cancer that has a specific genetic change (KRAS G12C mutation). The drug is designed to block the cancer's growth signal. About 116 participants will receive the treatment to see if it shrinks tumors and how safe…
Matched conditions: LUNG ADENOCARCINOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
New hope for advanced lung cancer: adding surgery or radiation to immunotherapy may boost survival
Disease control OngoingThis study tests whether adding local treatments like surgery or radiation to a two-drug immunotherapy regimen helps people with stage IV non-small cell lung cancer live longer. About 339 participants will receive either immunotherapy alone or immunotherapy plus local therapy. Th…
Matched conditions: LUNG ADENOCARCINOMA
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New cocktail for inoperable lung cancer shows promise in early trial
Disease control OngoingThis study tested a three-part treatment for people with stage III lung cancer that cannot be removed by surgery. The treatment combined standard chemotherapy (cisplatin and etoposide) with radiation, followed by two additional drugs (docetaxel and bevacizumab) to try to kill mor…
Matched conditions: LUNG ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:06 UTC